Eli Lilly stock could grow 76% in 3 years driven by blockbuster drugs and new sales channels.

Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new revenue last quarter, and a rapidly growing immunology, oncology, and neuroscience segment. However, price pressures and a potential decline in net margin pose risks. The launch of Lilly Employer Connect, a platform for businesses to offer obesity medications, may add further growth starting in late 2026. Investors should consider these factors and the risks of relying on a single stock when evaluating Eli Lilly.